There are two case reports of a paradoxical embolus to the brain following bone marrow infusion. 1 We describe a similar case following infusion of peripheral blood hematopoietic stem cells.
A 62-year-old man had been diagnosed with classical Hodgkin's lymphoma 5.2 years prior to admission. He was initially treated with ABVD chemotherapy, and achieved complete remission. He relapsed with neck and mediastinal lymphadenopathy 4 years later and was treated with ICE/ rituximab. Although initially thought to be disease-free following ICE/rituximab, he developed recurrent lymphadenopathy 3 months later, and was treated with gemcitabine-based salvage chemotherapy with good response. He was then mobilized with cyclophosphamide þ granulocyte colony-stimulating factor (G-CSF) and underwent two apheresis procedures to collect autologous hematopoietic stem cells (HSC) with a yield of 3.09 Â 10 6 CD34 þ cells per kilogram of patient weight, which were cryopreserved in 10% dimethyl sulfoxide (DMSO), human serum albumin, and Plasmalyte-A media. Following conditioning with cyclophosphamide, BCNU and etoposide, while being reinfused with the first thawed HSC product several weeks later, he suddenly felt nauseated and complained of abdominal pain. He decided not to volunteer these symptoms and continue with the infusion. At the end of the 220 ml infusion, he had a 'scratchy sensation' in his throat, which prompted him to cough repetitively. Subsequently, his nurse noticed a new right facial droop. He also complained of tingling in the index finger of his left hand. The patient denied a history of hypertension or previous strokes. He denied headache, chest pain, shortness of breath, palpitations, calf pain, dyspnea, or urticaria. Physical examination was remarkable for a central right facial nerve palsy and dysarthria. His body temperature remained unchanged at 36.81C throughout the transfusion. His heart rate remained approximately 90/min and his blood pressure ranged from 100/60 mmHg prior to infusion to 124/92 mmHg after its completion. With supportive care, his symptoms improved substantially over the first hour, with ongoing improvement over the subsequent 48 h. Computed tomography (CT) with angiography was performed immediately, followed by magnetic resonance imaging (MRI) approximately 12 h later; results were normal for both studies. Since he had only received 1.65 Â 10 6 CD34 þ cells/kg with the first infusion, the decision was made to infuse a second banked autologous HPSC product. The second product was washed, filtered, and caused no further reactions. Transthoracic echocardiography with bubble injection demonstrated intracardiac shunting suggestive of a small aortic septal defect or a patent foramen ovale (PFO). There was no evidence of deep vein thrombosis in the bilateral lower extremities by duplex ultrasound with Doppler study. The remainder of his hospital course was uncomplicated and to date he remains free of recurrent neurologic symptoms.
The patient developed toxicity secondary to the HSC product containing cryoprotectant DMSO, which can potentially cause gastrointestinal, cardiac or neurological reactions. He developed nausea, throat irritation and repetitive cough, which may transiently elevate central venous pressure (CVP). 1 The administration of volume during any type of transfusion may further increase the CVP in patients with a poorly compliant cardiovascular system. The associated rise in right atrial pressure may result in cardiac right-to-left-shunting of fibrous strands or clumped cells in the HSC product, leading to a cerebral paradoxical embolus due to a PFO. PFO is seen in all age groups, with a reported prevalence of 10-35%, 2 and should be considered if there is clinical suspicion for paradoxical embolism. For diagnosis, transesophageal echocardiography (TEE) with valsalva maneuver or bubble injection is superior to transthoracic echocardiography (TTE). However, TTE may be more readily available in most institutions and is a reasonable first step. If chosen as the initial diagnostic test, a negative TTE does not entirely exclude the presence of a PFO and one should proceed to TEE.
In patients at risk for paradoxical embolism due to PFO, filtration of cryopreserved stem cell products may be performed in order to remove possible debris. In addition, washing the product may reduce the amount of DMSO infused and the risk of an adverse reaction, although this may result in loss of efficacy of its therapeutic component and may not be an option in autologous transplant patients with low-yield HSC collections (ie 'poor mobilizers'). Under those circumstances, alternative measures that reduce the CVP and right atrial pressure should be considered, which include volume depletion through diuresis, a slower infusion rate and pharmacologic prevention of emesis or coughing. 1 Patients with large PFOs may benefit from transcatheter closure after presumed paradoxical embolism. 
